JUBLPHARMA.NS Cash Flow
Jubilant Pharmova Ltd.
Profit & Loss Balance Sheet Cash Flow
Cash Flow · 8 years on file
(FY2017-18 to FY2025-26)
· fetched 2026-08-23 23:33
| Line item | FY2017-18 | FY2019-20 | FY2020-21 standalone basis | FY2021-22 | FY2022-23 | FY2023-24 | FY2024-25 | FY2025-26 | Source (XBRL element) |
|---|---|---|---|---|---|---|---|---|---|
| Net Cash from Operating Activities | N/A | N/A | N/A | ₹837.54 Cr. | ₹660.67 Cr. | ₹971.30 Cr. | ₹1,072.10 Cr. | ₹1,226.80 Cr. | CashFlowsFromUsedInOperatingActivities |
| Net Cash from Investing Activities | N/A | N/A | N/A | ₹-380.37 Cr. | ₹-544.41 Cr. | ₹-607.90 Cr. | ₹487.70 Cr. | ₹-1,260.00 Cr. | CashFlowsFromUsedInInvestingActivities |
| Net Cash from Financing Activities | N/A | N/A | N/A | ₹-32.60 Cr. | ₹-156.69 Cr. | ₹-432.50 Cr. | ₹-1,452.70 Cr. | ₹94.90 Cr. | CashFlowsFromUsedInFinancingActivities |
| Effect of Exchange Rate Changes | N/A | N/A | N/A | ₹57.29 Cr. | ₹70.53 Cr. | ₹11.60 Cr. | ₹24.80 Cr. | ₹117.10 Cr. | EffectOfExchangeRateChangesOnCashAndCashEquivalents |
| Net Increase/(Decrease) in Cash | N/A | N/A | N/A | ₹481.86 Cr. | ₹30.10 Cr. | ₹-57.50 Cr. | ₹131.90 Cr. | ₹178.80 Cr. | IncreaseDecreaseInCashAndCashEquivalents |
| Cash and Cash Equivalents (Closing) | N/A | N/A | N/A | ₹501.96 Cr. | ₹983.82 Cr. | ₹1,013.90 Cr. | N/A | N/A | CashAndCashEquivalentsCashFlowStatement |
Every figure above is the exact value of the named XBRL element from JUBLPHARMA.NS's cached filing for that year — nothing here is estimated or backfilled. A company shows one column per year StockProof actually has data for — never padded with blank years. Rows shown as N/A are genuinely not disclosed under that year's filing format (see peer comparison for how other Healthcare companies compare).